Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
naltrexone + baclofen
- Development stage
- Preclinical
- Lead developer
- Pharnext
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of naltrexone, an opioid receptor antagonist, and baclofen, a GABA-B receptor agonist, being investigated for the treatment of alcohol use disorder. The combination may produce synergistic effects in reducing alcohol consumption by simultaneously blocking the rewarding effects of alcohol through opioid receptor antagonism and addressing symptoms like anxiety and irritability through GABA-B receptor activation.
02
Targets
DOR (Opioid Receptor Delta 1)MOR (Mu opioid receptor)GABA-B (Gamma-aminobutyric acid receptor type B)KOR (Kappa opioid receptor)
Beyond the preview
Go deeper on naltrexone + baclofen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on naltrexone + baclofen.